Delivery Order SPE2DB20D9214-SPE2DB25FD4WP
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $18,019.40 by the Defense Logistics Agency (DLA) for the supply of Prolastin C 1,000 mg/20 ml vials. The contract employs firm fixed-price pricing with an ultimate completion date of September 8, 2025. This delivery order was issued without a set-aside designation, reflecting the company's competitive positioning within federal...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $27,403.64 for Prolastin C 1,000 mg/20 ml vials. The award, issued on August 25, 2025, with an ultimate completion date of September 16, 2025, carries no set-aside designation. The contract is funded through the Defense Logistics Agency's Medical Supply Chain operations, which serves as the government's primary source for...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $15,860.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $18,149.94 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation. The award represents a discrete purchase order issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order valued at $35,824.80 to DMS Pharmaceutical Group Inc. on June 16, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, with an ultimate completion date of July 9, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contract vehicle with DLA. The award carries no set-aside designation, allowing the woman-owned small business to compete on an unrestricted...
- The Defense Logistics Agency awarded a delivery order valued at $36,122.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contractual relationship with the...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,132.25 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries an ultimate completion date of September 30, 2025, and was awarded on September 9, 2025, with no set-aside designation applied. DMS Pharmaceutical Group will perform the work at its Park Ridge facility, delivering...
- The Defense Logistics Agency awarded a delivery order valued at $17,604.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on June 12, 2025, with an ultimate completion date of July 7, 2025, represents a discrete procurement action under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA. The contract...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, valued at $18,238.39, was awarded on August 7, 2025, with an ultimate completion date of August 28, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $17,365.20 contract is for the delivery of Prolastin C, a 1,000 mg/20 ml pharmaceutical product, with a completion date of July 8, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
- SPE2DB20D9214Indefinite Delivery Contract
- SPE2DB20D9214-SPE2DB25FD4WPDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $18,273.77 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a continuation of DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain. The award carries no set-aside designation, allowing the company to compete on an unrestricted basis. Performance will occur at the vendor's facility in Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, a $499.999 billion agreement valid through November 2026 that authorizes the agency to procure a comprehensive range of pharmaceutical products to support Department of Defense healthcare facilities worldwide. The SPE2DB program enables firm fixed-price delivery orders for branded and generic prescription drugs, biologics, medical consumables, and specialty medications. Prolastin C, an alpha-1 proteinase inhibitor therapy used in the treatment of genetic emphysema, exemplifies the specialized pharmaceutical products distributed through this arrangement to military health system facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.3k | 7/24/25 |